13:30 , Dec 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample and mouse studies suggest inhibiting the Notch pathway components HES1, γ secretase, MAML1 and NCSTN could help treat NASH. In NASH patient liver tissue samples, hepatocyte levels of HES1...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Ayala reports Phase Ib data for AL101 in solid tumors

Ayala Pharmaceuticals Inc. (Rehovot, Israel) said once-weekly 4 mg IV AL101 (formerly BMS-906024) led to a complete response in a patient with gastroesophageal junction adenocarcinoma in a Phase Ib trial to treat locally advanced or...